Given the mixed findings in the literature regarding AFP and NAFLD, our study contributes to a more nuanced understanding of liver disease progression in specific patient populations, highlighting the importance of context in interpreting biomarker data. The gene discussed is AFP; the disease is metabolic dysfunction-associated steatotic liver disease.